Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathwayJie Li, Liying Xue|Oncology Letters|2019Cited by 18
Dual PI3K/mTOR inhibitor NVP‑BEZ235 decreases the proliferation of doxorubicin‑resistant K562 cellsJie Li, Liying Xue|Molecular Medicine Reports|2021Cited by 18